Schreck KC - Search Results

1

Druggable genomic landscapes of high-grade gliomas.

Ghanem P, Fatteh M, Kamson DO, Balan A, Chang M, Tao J, Blakeley J; Johns Hopkins Molecular Tumor Board Investigators; Canzoniero J, Grossman SA, Marrone K, Schreck KC, Anagnostou V. Ghanem P, et al. Among authors: schreck kc. Front Med (Lausanne). 2023 Dec 8;10:1254955. doi: 10.3389/fmed.2023.1254955. eCollection 2023. Front Med (Lausanne). 2023. PMID: 38143440 Free PMC article.

2

Point/counterpoint: randomized versus single-arm phase II clinical trials for patients with newly diagnosed glioblastoma.

Grossman SA, Schreck KC, Ballman K, Alexander B. Grossman SA, et al. Among authors: schreck kc. Neuro Oncol. 2017 Apr 1;19(4):469-474. doi: 10.1093/neuonc/nox030. Neuro Oncol. 2017. PMID: 28388713 Free PMC article. No abstract available.

3

Effect of ketogenic diets on leukocyte counts in patients with epilepsy.

Schreck KC, Lwin M, Strowd RE, Henry-Barron BJ, Blakeley JO, Cervenka MC. Schreck KC, et al. Nutr Neurosci. 2019 Jul;22(7):522-527. doi: 10.1080/1028415X.2017.1416740. Epub 2017 Dec 18. Nutr Neurosci. 2019. PMID: 29254457

4

Concurrent BRAF/MEK Inhibitors in BRAF V600-Mutant High-Grade Primary Brain Tumors.

Schreck KC, Guajardo A, Lin DDM, Eberhart CG, Grossman SA. Schreck KC, et al. J Natl Compr Canc Netw. 2018 Apr;16(4):343-347. doi: 10.6004/jnccn.2017.7052. J Natl Compr Canc Netw. 2018. PMID: 29632053

5

Role of Temozolomide in the Treatment of Cancers Involving the Central Nervous System.

Schreck KC, Grossman SA. Schreck KC, et al. Oncology (Williston Park). 2018 Nov 15;32(11):555-60, 569. Oncology (Williston Park). 2018. PMID: 30474103 Free article. Review.

6

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.

Schreck KC, Grossman SA, Pratilas CA. Schreck KC, et al. Cancers (Basel). 2019 Aug 28;11(9):1262. doi: 10.3390/cancers11091262. Cancers (Basel). 2019. PMID: 31466300 Free PMC article. Review.

7

RAF and MEK inhibitor therapy in adult patients with brain tumors: a case-based overview and practical management of adverse events.

Schreck KC, Patel MP, Wemmer J, Grossman SA, Peters KB. Schreck KC, et al. Neurooncol Pract. 2020 Jul;7(4):369-375. doi: 10.1093/nop/npaa006. Epub 2020 Feb 27. Neurooncol Pract. 2020. PMID: 32765888 Free PMC article. Review.

8

Combination MEK and mTOR inhibitor therapy is active in models of glioblastoma.

Schreck KC, Allen AN, Wang J, Pratilas CA. Schreck KC, et al. Neurooncol Adv. 2020 Oct 15;2(1):vdaa138. doi: 10.1093/noajnl/vdaa138. eCollection 2020 Jan-Dec. Neurooncol Adv. 2020. PMID: 33235998 Free PMC article.

9

Pembrolizumab for patients with leptomeningeal metastasis from solid tumors: efficacy, safety, and cerebrospinal fluid biomarkers.

Naidoo J, Schreck KC, Fu W, Hu C, Carvajal-Gonzalez A, Connolly RM, Santa-Maria CA, Lipson EJ, Holdhoff M, Forde PM, Douville C, Riemer J, Barnes A, Redmond KJ, Kleinberg L, Page B, Aygun N, Kinzler KW, Papadopoulos N, Bettegowda C, Venkatesan A, Brahmer JR, Grossman SA. Naidoo J, et al. Among authors: schreck kc. J Immunother Cancer. 2021 Aug;9(8):e002473. doi: 10.1136/jitc-2021-002473. J Immunother Cancer. 2021. PMID: 34380662 Free PMC article.

10

Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAF^V600E-Mutant Human Glioma.

Schreck KC, Morin A, Zhao G, Allen AN, Flannery P, Glantz M, Green AL, Jones C, Jones KL, Kilburn LB, Nazemi KJ, Samuel D, Sanford B, Solomon DA, Wang J, Pratilas CA, Nicolaides T, Mulcahy Levy JM. Schreck KC, et al. Clin Cancer Res. 2021 Nov 15;27(22):6197-6208. doi: 10.1158/1078-0432.CCR-21-2660. Epub 2021 Aug 25. Clin Cancer Res. 2021. PMID: 34433654 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

44 results

Search Page